AIM: The aim of this study was to detect circulating anti-carcinoembryonic antigen antibodies (anti-CEA) in breast cancer patients and to evaluate their clinical and prognostic significance. METHODS: Fifty-two breast cancer patients and 28 controls were included in this study. Detection of anti-CEA antibodies was performed using a modified enzyme linked immunoassay (ELISA). Sensitivity, specificity and usefulness index of anti-CEA antibodies were compared to those of CEA. The correlation of anti-CEA antibodies with survival and recurrence-free survival was tested with univariate and multivariate analysis. RESULTS: Anti-CEA was present in 57% of breast cancer patients and in 11% of controls. The sensitivity and usefulness index of anti-CEA were significantly better than those of CEA. The specificity of anti-CEA antibodies was less than that of CEA, the difference not being statistically significant. Anti-CEA antibodies were an independent statistically significant, favourable factor in recurrence-free survival. CONCLUSION: Anti-CEA antibodies circulate in breast cancer patients. They could be used as a more sensitive tumour marker than CEA. Their presence is associated with improved recurrence-free survival. These results should be confirmed in a larger series. Copyright 2000 Harcourt Publishers Ltd.
AIM: The aim of this study was to detect circulating anti-carcinoembryonic antigen antibodies (anti-CEA) in breast cancerpatients and to evaluate their clinical and prognostic significance. METHODS: Fifty-two breast cancerpatients and 28 controls were included in this study. Detection of anti-CEA antibodies was performed using a modified enzyme linked immunoassay (ELISA). Sensitivity, specificity and usefulness index of anti-CEA antibodies were compared to those of CEA. The correlation of anti-CEA antibodies with survival and recurrence-free survival was tested with univariate and multivariate analysis. RESULTS: Anti-CEA was present in 57% of breast cancerpatients and in 11% of controls. The sensitivity and usefulness index of anti-CEA were significantly better than those of CEA. The specificity of anti-CEA antibodies was less than that of CEA, the difference not being statistically significant. Anti-CEA antibodies were an independent statistically significant, favourable factor in recurrence-free survival. CONCLUSION: Anti-CEA antibodies circulate in breast cancerpatients. They could be used as a more sensitive tumour marker than CEA. Their presence is associated with improved recurrence-free survival. These results should be confirmed in a larger series. Copyright 2000 Harcourt Publishers Ltd.
Authors: Denong Wang; Xiaohe Liu; Ben Hsieh; Richard Bruce; George Somlo; Jiaoti Huang; Lidia Sambucetti Journal: Arch Med Res Date: 2015-12-01 Impact factor: 2.235
Authors: Lavakumar Karyampudi; Christopher J Krco; Kimberly R Kalli; Courtney L Erskine; Lynn C Hartmann; Karin Goodman; James N Ingle; Matthew J Maurer; Aziza Nassar; Chao Yu; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson Journal: Cancer Immunol Immunother Date: 2009-07-21 Impact factor: 6.968